Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595

COLOPLAST A/S (COLO B)

Delayed Quote. Delayed  - 08/30 09:12:57 am
508 DKK   --.--%
08/16 COLOPLAST A/S : delivers 9M result in line with guidance
08/16 COLOPLAST A/S : Share buy-back
08/11COLOPLAST A/S : quaterly earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Coloplast A/S : Patent Issued for Method of Treating Peyronie'S Disease (USPTO 9408696)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/18/2016 | 07:17pm CEST

By a News Reporter-Staff News Editor at Biotech Week -- Coloplast A/S (Humlebaek, DK) has been issued patent number 9408696, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also Coloplast A/S).

The patent's inventors are Deitch, Sarah J (Minneapolis, MN); Kerkvliet, Julie M (Otsego, MN).

This patent was filed on September 29, 2013 and was published online on August 9, 2016.

From the background information supplied by the inventors, news correspondents obtained the following quote: "Peyronie's disease is manifested by an abnormal bend that occurs in the erect penis of the sufferer and can be associated with painful erection and/or painful intercourse.

"Peyronie's disease is related to the development of scar tissue, or plaques, that form on tissues (e.g., tunica albuginea) inside the penis. One non-surgical approach for the treatment of Peyronie's disease includes injecting drugs into the plaques that lessen the compression applied by the plaques to the erect penis. The research and efficacy of this approach is limited.

"Surgical treatments for Peyronie's disease include excising portions of the tunica albuginea from the penis opposite the plaque and closing the fenestrations with sutures. Access to the tunica albuginea is achieved by first degloving the penile skin away from the penis to expose the Buck's fascia and tunica albuginea along the length of the penis. Degloving the penile skin is painful and the recovery time for the patient can be several weeks. Although the long term results of this surgical approach are good, both short term (within 8 weeks) and long term failures can present with residual penile deformity.

"Another surgical treatment includes corporal plication in which plication sutures are placed on the contralateral side of the plaque without excising the tunica albuginea or removing the plaque. Corporal plication is most commonly employed subsequent to a previous Peyronie's treatment surgery to correct small angles of residual penile deformity.

"Patients and clinicians desire more effective treatments for Peyronie's disease."

Supplementing the background information on this patent, NewsRx reporters also obtained the inventors' summary information for this patent: "One aspect provides an implant that includes one or more sheet components attached to at least one reinforcing component. The at least one reinforcing component provides column strength to the implant and the one or more sheet components provides support for penile tissue. The implant is adapted to be positioned on a Peyronie's plaques affected area of a penis. The implant is configured to elongate during an erection of the penis and to contract when the penis returns to its flaccid state.

"One aspect provides an implant for treatment of Peyronie's disease. The implant includes a skeletal framework having one or more sheet components attached to at least one reinforcing component to support penile tissue and to provide a flexible, yet strong and durable implant. The sheet components are at least partly made from a biocompatible material. The implant is placed subcutaneously on an affected area of the penis. The skeletal framework of the implant allows for elongation of the implant during erection of the penis and for contraction of the implant when the penis is returning to its flaccid state. To secure the implant to the penis, the skeletal framework includes at least one attachment mechanism.

"One aspect provides an implant that includes a skeletal framework having one or more sheet components attached to a plurality of reinforcing components that provide column strength along a longitudinal direction of the implant and the sheet components provide support for penile tissue. The skeletal framework of the implant allows for elongation of the implant during erection of the penis and for contraction of the implant when the penis is returning to its flaccid state.

"One aspect provides an implant that includes a skeletal framework having one or more sheet components attached to at least one reinforcing component that provide support for penile tissue and column strength to the implant, respectively. The implant is configured to be placed underneath the upper skin layer of the penis (e.g. on the tunica albuginea, T.A.) on an affected area of the penis and forms an arch describing 180 degrees or less.

"One aspect provides an implant that includes a skeletal framework having one or more sheet components attached to a plurality of reinforcing components and at least one attachment mechanism including a suture line attached to the skeletal framework at one end and a hook-shaped needle for tissue penetration attached at a second end of the suture line and at least one anchor provided on the suture line for securing the implant to the penis.

"One aspect provides a method of treating Peyronie's disease. The method includes implanting an implant including one or more sheet components attached to a reinforcing component. The method includes performing an incision to gain access to the penile tissue affected by the Peyronie's plaques and excising the scar tissue. The method includes providing the implant on the affected area. The method includes positioning the implant so as to provide for optimal tissue ingrowth and for optimizing column strength in the implant. The method includes securing the implant to the penis. The method includes closing the incision.

"Embodiments provide an implant that eliminates or reduces the physical effects of the Peyronie's disease. Embodiments of the implant described in this application have improved sustainability and durability and thus reduces or eliminates the potential for surgical revision and/or substitution of the implant. A further object is to provide a Peyronie's treatment implant that is easily manageable and has improved flexibility in order to improve patient perception and comfort. A further object is to provide an implant that supports and reinforces the affected penile tissue area where the plaques have been removed. A still further object is to provide an implant that is easily implantable and obviates the use of other tools to attach the implant to the penile tissue. A further objective is to provide another alternative to a medicament based treatment option for Peyronie's disease."

For the URL and additional information on this patent, see: Deitch, Sarah J; Kerkvliet, Julie M. Method of Treating Peyronie'S Disease. U.S. Patent Number 9408696, filed September 29, 2013, and published online on August 9, 2016. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9408696.PN.&OS=PN/9408696RS=PN/9408696

Keywords for this news article include: Coloplast A/S, Peyronie's Disease.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COLOPLAST A/S
08/18 COLOPLAST A/S : Patent Issued for Method of Treating Peyronie'S Disease (USPTO 9..
08/16 COLOPLAST A/S : delivers 9M result in line with guidance
08/16 COLOPLAST A/S : Share buy-back
08/11COLOPLAST A/S : quaterly earnings release
08/08 COLOPLAST A/S : Share buy-back
08/01 COLOPLAST A/S : Share buy-back
07/25 COLOPLAST A/S : Share buy-back
07/11 COLOPLAST A/S : Share buy-back
07/07 COLOPLAST A/S : Patent Issued for Artificial Urinary Sphincter Having a Multi-Co..
07/04 COLOPLAST A/S : Share buy-back
More news
Sector news : Medical Equipment Wholesale
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Report Its Heart Devices Are Vulnerable to Cyber..
08/26DJST JUDE MEDICAL : . Jude Denies Report Its Heart Devices Are Vulnerable to Cyber..
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
More sector news : Medical Equipment Wholesale
News from SeekingAlpha
07/06 Sun Comes Out For Big-Cap Medtechs As Investors Seek Refuge From Market Squal..
07/03 These stocks should generate superior ROE and FCF - Barclays
2015 GIVING UP A HOBBY : Putting My Portfolio On Autopilot
2015 THE GLOBAL X FTSE NORDIC REGION ETF : The Perfect Fit
2015 Coloplast Is A Rare Story On Multiple Levels
Advertisement
Financials ( DKK)
Sales 2016 14 777 M
EBIT 2016 4 878 M
Net income 2016 3 716 M
Finance 2016 290 M
Yield 2016 2,72%
P/E ratio 2016 28,92
P/E ratio 2017 26,10
EV / Sales 2016 6,79x
EV / Sales 2017 6,32x
Capitalization 100 584 M
More Financials
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | 4-Traders
Full-screen chart
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 528  DKK
Spread / Average Target 4,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Søren Rasmussen President & Chief Executive Officer
Michael Pram Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard CFO, EVP & Head-Investor Relations
Oliver Johansen Senior VP-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COLOPLAST A/S-9.61%15 092
HENRY SCHEIN, INC.3.81%13 433
PATTERSON COMPANIES, I..2.52%4 598
AMPLIFON SPA15.63%2 327
OWENS & MINOR, INC.-5.70%2 117
SHIP HEALTHCARE HOLDIN..-10.42%1 375
More Results